Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease

Rolf Kreutz, Abbas Bitar, Janelle Owens, Zeruesenay Desta, Jeffrey Breall, Elisabeth von der Lohe, Anjan Sinha, Matteo Vatta, Perry Nystrom, Yan Jin, David A. Flockhart

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accelerated fibrin stabilization and reduced rate of fibrinolysis. The contribution of Val34Leu to long term risk of recurrent myocardial infarction (MI) in patients with coronary stenting has not been conclusively established. The objective of the study was to examine the effects of Val34Leu on fibrin generation, platelet aggregation, and long term clinical outcomes in patients with coronary artery disease treated with dual antiplatelet therapy. Patients with angiographically documented coronary artery disease who were treated with aspirin and clopidogrel were enrolled (n = 211). Light transmittance aggregometry and plasma fibrin clot formation using thrombelastography (TEG) were determined. Genotyping of Val34Leu was performed using Taqman assay. Clinical events during follow up were recorded. Homozygous carriers of 34Leu variant had significantly shorter fibrin clot formation time as compared to wild type individuals (TEG K: 1.27 ± 0.3 vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was associated with gene dose dependent increased risk of MI (log rank, p = 0.002) or occurrence of composite of MI and CV death (log rank, p = 0.005) with highest event rates observed in homozygous carriers of 34Leu. In summary, FXIII Val34Leu polymorphism was associated with increased rate of fibrin stabilization in homozygous carriers of the variant and may increase risk of recurrent MI and death in patients with angiographically established coronary artery disease treated with dual antiplatelet therapy.

Original languageEnglish
Pages (from-to)380-387
Number of pages8
JournalJournal of Thrombosis and Thrombolysis
Volume38
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Factor XIII
Fibrin
Coronary Artery Disease
Myocardial Infarction
Thrombelastography
clopidogrel
Fibrinolysis
Platelet Aggregation
Aspirin
Single Nucleotide Polymorphism
Light
Therapeutics

Keywords

  • Acute myocardial infarction
  • Coagulation
  • Genetic polymorphism
  • Platelet function tests
  • Thrombelastography

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. / Kreutz, Rolf; Bitar, Abbas; Owens, Janelle; Desta, Zeruesenay; Breall, Jeffrey; von der Lohe, Elisabeth; Sinha, Anjan; Vatta, Matteo; Nystrom, Perry; Jin, Yan; Flockhart, David A.

In: Journal of Thrombosis and Thrombolysis, Vol. 38, No. 3, 2014, p. 380-387.

Research output: Contribution to journalArticle

@article{4dcee0e5d44d40758502222db118aad0,
title = "Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease",
abstract = "Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accelerated fibrin stabilization and reduced rate of fibrinolysis. The contribution of Val34Leu to long term risk of recurrent myocardial infarction (MI) in patients with coronary stenting has not been conclusively established. The objective of the study was to examine the effects of Val34Leu on fibrin generation, platelet aggregation, and long term clinical outcomes in patients with coronary artery disease treated with dual antiplatelet therapy. Patients with angiographically documented coronary artery disease who were treated with aspirin and clopidogrel were enrolled (n = 211). Light transmittance aggregometry and plasma fibrin clot formation using thrombelastography (TEG) were determined. Genotyping of Val34Leu was performed using Taqman assay. Clinical events during follow up were recorded. Homozygous carriers of 34Leu variant had significantly shorter fibrin clot formation time as compared to wild type individuals (TEG K: 1.27 ± 0.3 vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was associated with gene dose dependent increased risk of MI (log rank, p = 0.002) or occurrence of composite of MI and CV death (log rank, p = 0.005) with highest event rates observed in homozygous carriers of 34Leu. In summary, FXIII Val34Leu polymorphism was associated with increased rate of fibrin stabilization in homozygous carriers of the variant and may increase risk of recurrent MI and death in patients with angiographically established coronary artery disease treated with dual antiplatelet therapy.",
keywords = "Acute myocardial infarction, Coagulation, Genetic polymorphism, Platelet function tests, Thrombelastography",
author = "Rolf Kreutz and Abbas Bitar and Janelle Owens and Zeruesenay Desta and Jeffrey Breall and {von der Lohe}, Elisabeth and Anjan Sinha and Matteo Vatta and Perry Nystrom and Yan Jin and Flockhart, {David A.}",
year = "2014",
doi = "10.1007/s11239-014-1059-4",
language = "English",
volume = "38",
pages = "380--387",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease

AU - Kreutz, Rolf

AU - Bitar, Abbas

AU - Owens, Janelle

AU - Desta, Zeruesenay

AU - Breall, Jeffrey

AU - von der Lohe, Elisabeth

AU - Sinha, Anjan

AU - Vatta, Matteo

AU - Nystrom, Perry

AU - Jin, Yan

AU - Flockhart, David A.

PY - 2014

Y1 - 2014

N2 - Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accelerated fibrin stabilization and reduced rate of fibrinolysis. The contribution of Val34Leu to long term risk of recurrent myocardial infarction (MI) in patients with coronary stenting has not been conclusively established. The objective of the study was to examine the effects of Val34Leu on fibrin generation, platelet aggregation, and long term clinical outcomes in patients with coronary artery disease treated with dual antiplatelet therapy. Patients with angiographically documented coronary artery disease who were treated with aspirin and clopidogrel were enrolled (n = 211). Light transmittance aggregometry and plasma fibrin clot formation using thrombelastography (TEG) were determined. Genotyping of Val34Leu was performed using Taqman assay. Clinical events during follow up were recorded. Homozygous carriers of 34Leu variant had significantly shorter fibrin clot formation time as compared to wild type individuals (TEG K: 1.27 ± 0.3 vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was associated with gene dose dependent increased risk of MI (log rank, p = 0.002) or occurrence of composite of MI and CV death (log rank, p = 0.005) with highest event rates observed in homozygous carriers of 34Leu. In summary, FXIII Val34Leu polymorphism was associated with increased rate of fibrin stabilization in homozygous carriers of the variant and may increase risk of recurrent MI and death in patients with angiographically established coronary artery disease treated with dual antiplatelet therapy.

AB - Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accelerated fibrin stabilization and reduced rate of fibrinolysis. The contribution of Val34Leu to long term risk of recurrent myocardial infarction (MI) in patients with coronary stenting has not been conclusively established. The objective of the study was to examine the effects of Val34Leu on fibrin generation, platelet aggregation, and long term clinical outcomes in patients with coronary artery disease treated with dual antiplatelet therapy. Patients with angiographically documented coronary artery disease who were treated with aspirin and clopidogrel were enrolled (n = 211). Light transmittance aggregometry and plasma fibrin clot formation using thrombelastography (TEG) were determined. Genotyping of Val34Leu was performed using Taqman assay. Clinical events during follow up were recorded. Homozygous carriers of 34Leu variant had significantly shorter fibrin clot formation time as compared to wild type individuals (TEG K: 1.27 ± 0.3 vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was associated with gene dose dependent increased risk of MI (log rank, p = 0.002) or occurrence of composite of MI and CV death (log rank, p = 0.005) with highest event rates observed in homozygous carriers of 34Leu. In summary, FXIII Val34Leu polymorphism was associated with increased rate of fibrin stabilization in homozygous carriers of the variant and may increase risk of recurrent MI and death in patients with angiographically established coronary artery disease treated with dual antiplatelet therapy.

KW - Acute myocardial infarction

KW - Coagulation

KW - Genetic polymorphism

KW - Platelet function tests

KW - Thrombelastography

UR - http://www.scopus.com/inward/record.url?scp=84906939471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906939471&partnerID=8YFLogxK

U2 - 10.1007/s11239-014-1059-4

DO - 10.1007/s11239-014-1059-4

M3 - Article

VL - 38

SP - 380

EP - 387

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 3

ER -